TY - JOUR
T1 - Depressed plasma platelet-activating factor acetylhydrolase in patients presenting with acute myocardial infarction
AU - Serebruany, Victor L.
AU - Gurbel, Paul A.
AU - Murugesan, Selva R.
AU - Lowry, David R.
AU - Sturm, Ekkehard
AU - Svetlov, Stanislav I.
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1998/10
Y1 - 1998/10
N2 - Cell membrane phospholipids, including platelet-activating factor (PAF), participate in the pathogenesis of acute myocardial infarction (AMI). The plasma level of PAF acetylhydrolase (AH) was determined in 18 patients at presentation with AMI before thrombolysis, and the administration of adjunctive therapy, and compared with 13 healthy controls. Plasma levels of PAF-AH were significantly lower in the AMI patients (23.15 ± 1.75 nmol/min/ml) than in the controls(30.43 ± 2.13 nmol/min/ml; p = 0.027). Considering normal plasma levels of PAF and lyso-PAF, and lack of evidence that anti-PAF antibodies are really beneficial in myocardial ischemia-reperfusion, it is reasonable to speculate that an inability of systemic PAF to 'turn on' PAF-AH enzymatic activity could contribute substantially to the observed events. Decreased PAF-AH activity in AMI patients may represent not a consequence, but rather, a risk factor for the development of acute coronary syndromes.
AB - Cell membrane phospholipids, including platelet-activating factor (PAF), participate in the pathogenesis of acute myocardial infarction (AMI). The plasma level of PAF acetylhydrolase (AH) was determined in 18 patients at presentation with AMI before thrombolysis, and the administration of adjunctive therapy, and compared with 13 healthy controls. Plasma levels of PAF-AH were significantly lower in the AMI patients (23.15 ± 1.75 nmol/min/ml) than in the controls(30.43 ± 2.13 nmol/min/ml; p = 0.027). Considering normal plasma levels of PAF and lyso-PAF, and lack of evidence that anti-PAF antibodies are really beneficial in myocardial ischemia-reperfusion, it is reasonable to speculate that an inability of systemic PAF to 'turn on' PAF-AH enzymatic activity could contribute substantially to the observed events. Decreased PAF-AH activity in AMI patients may represent not a consequence, but rather, a risk factor for the development of acute coronary syndromes.
KW - Acute myocardial infarction, human
KW - Platelet-activating factor
KW - Platelet-activating factor acetylhydrolase
UR - http://www.scopus.com/inward/record.url?scp=0031763395&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031763395&partnerID=8YFLogxK
U2 - 10.1159/000006831
DO - 10.1159/000006831
M3 - Article
C2 - 9778550
AN - SCOPUS:0031763395
VL - 90
SP - 127
EP - 130
JO - Cardiology (Switzerland)
JF - Cardiology (Switzerland)
SN - 0008-6312
IS - 2
ER -